Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival
Clear progress has been made in the adjuvant treatment of colon cancer. Until very recently, the absolute benefit for survival obtained with the administration of 6 months’ FU/LV compared with control was about 6%. Fluoropyrimidines have been shown to be at least as active and can replace intravenou...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases (Basel) 2007-01, Vol.25 (1), p.67-75 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 75 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Digestive diseases (Basel) |
| container_volume | 25 |
| creator | Samantas, E. Dervenis, C. Rigatos, S.K. |
| description | Clear progress has been made in the adjuvant treatment of colon cancer. Until very recently, the absolute benefit for survival obtained with the administration of 6 months’ FU/LV compared with control was about 6%. Fluoropyrimidines have been shown to be at least as active and can replace intravenous FU/LV in stage III colon cancer. Based on the results of the MOSAIC and NSABP C-07 trials, the addition of oxaliplatin to FU/LV improves disease-free survival and FOLFOX for 6 months can be recommended as adjuvant treatment for patients with stage III colon cancer. The benefit of adjuvant chemotherapy in stage II disease is limited and it should be proposed in patients with high-risk features. Adjuvant treatment of colon cancer improving and the use of genetic/molecular markers with the new targeted therapies may further improve survival. |
| doi_str_mv | 10.1159/000099172 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000099172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70303437</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-bd6d3e0e0461b6f65cb66a0a838aa20a062f2d647cdb4449894ef8275bc801ea3</originalsourceid><addsrcrecordid>eNpFkMtLw0AQxtcX9qEHz4LkJHiI7ns33kqoWix4UM9hk0xsah51Nwn0v3elpc5lhpnffMx8CF0RfE-IiB6wjygiih6hCWNEY8KFEsdoTDglYaSVOPEDjYXQVFF6isaYChVSJdgITZxbY-xllDxHI6KY5oLgMXqd5et-ME0XxCuo224F1my2QdHaIG6rtgli02RgH4P5UObgy8D3FvXGtgPU4NfKJnjv7VAOprpAZ4WpHFzu8xR9Ps0_4pdw-fa8iGfLMGMy6sI0lzkDDJhLkspCiiyV0mCjmTaGYoMlLWguucrylHMe6YhD4V8SaeZ_BsOm6Han66_46cF1SV26DKrKNND2LlGYYcaZ8uDdDsxs65yFItnYsjZ2mxCc_HmaHDz17M1etE9ryP_JvVUeuN4B38Z-gT0Au_VfIMd0_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70303437</pqid></control><display><type>article</type><title>Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival</title><source>Karger Journals</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Samantas, E. ; Dervenis, C. ; Rigatos, S.K.</creator><creatorcontrib>Samantas, E. ; Dervenis, C. ; Rigatos, S.K.</creatorcontrib><description>Clear progress has been made in the adjuvant treatment of colon cancer. Until very recently, the absolute benefit for survival obtained with the administration of 6 months’ FU/LV compared with control was about 6%. Fluoropyrimidines have been shown to be at least as active and can replace intravenous FU/LV in stage III colon cancer. Based on the results of the MOSAIC and NSABP C-07 trials, the addition of oxaliplatin to FU/LV improves disease-free survival and FOLFOX for 6 months can be recommended as adjuvant treatment for patients with stage III colon cancer. The benefit of adjuvant chemotherapy in stage II disease is limited and it should be proposed in patients with high-risk features. Adjuvant treatment of colon cancer improving and the use of genetic/molecular markers with the new targeted therapies may further improve survival.</description><identifier>ISSN: 0257-2753</identifier><identifier>ISBN: 3805582722</identifier><identifier>ISBN: 9783805582728</identifier><identifier>EISSN: 1421-9875</identifier><identifier>EISBN: 3318014575</identifier><identifier>EISBN: 9783318014570</identifier><identifier>DOI: 10.1159/000099172</identifier><identifier>PMID: 17384510</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Antineoplastic Agents - therapeutic use ; Chemotherapy, Adjuvant ; Colonic Neoplasms - drug therapy ; Drug Administration Routes ; Humans ; Neoplasm Staging ; Review Article ; Survival Analysis</subject><ispartof>Digestive diseases (Basel), 2007-01, Vol.25 (1), p.67-75</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>Copyright 2007 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-bd6d3e0e0461b6f65cb66a0a838aa20a062f2d647cdb4449894ef8275bc801ea3</citedby><cites>FETCH-LOGICAL-c369t-bd6d3e0e0461b6f65cb66a0a838aa20a062f2d647cdb4449894ef8275bc801ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17384510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samantas, E.</creatorcontrib><creatorcontrib>Dervenis, C.</creatorcontrib><creatorcontrib>Rigatos, S.K.</creatorcontrib><title>Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival</title><title>Digestive diseases (Basel)</title><addtitle>Dig Dis</addtitle><description>Clear progress has been made in the adjuvant treatment of colon cancer. Until very recently, the absolute benefit for survival obtained with the administration of 6 months’ FU/LV compared with control was about 6%. Fluoropyrimidines have been shown to be at least as active and can replace intravenous FU/LV in stage III colon cancer. Based on the results of the MOSAIC and NSABP C-07 trials, the addition of oxaliplatin to FU/LV improves disease-free survival and FOLFOX for 6 months can be recommended as adjuvant treatment for patients with stage III colon cancer. The benefit of adjuvant chemotherapy in stage II disease is limited and it should be proposed in patients with high-risk features. Adjuvant treatment of colon cancer improving and the use of genetic/molecular markers with the new targeted therapies may further improve survival.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Chemotherapy, Adjuvant</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Drug Administration Routes</subject><subject>Humans</subject><subject>Neoplasm Staging</subject><subject>Review Article</subject><subject>Survival Analysis</subject><issn>0257-2753</issn><issn>1421-9875</issn><isbn>3805582722</isbn><isbn>9783805582728</isbn><isbn>3318014575</isbn><isbn>9783318014570</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtLw0AQxtcX9qEHz4LkJHiI7ns33kqoWix4UM9hk0xsah51Nwn0v3elpc5lhpnffMx8CF0RfE-IiB6wjygiih6hCWNEY8KFEsdoTDglYaSVOPEDjYXQVFF6isaYChVSJdgITZxbY-xllDxHI6KY5oLgMXqd5et-ME0XxCuo224F1my2QdHaIG6rtgli02RgH4P5UObgy8D3FvXGtgPU4NfKJnjv7VAOprpAZ4WpHFzu8xR9Ps0_4pdw-fa8iGfLMGMy6sI0lzkDDJhLkspCiiyV0mCjmTaGYoMlLWguucrylHMe6YhD4V8SaeZ_BsOm6Han66_46cF1SV26DKrKNND2LlGYYcaZ8uDdDsxs65yFItnYsjZ2mxCc_HmaHDz17M1etE9ryP_JvVUeuN4B38Z-gT0Au_VfIMd0_g</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Samantas, E.</creator><creator>Dervenis, C.</creator><creator>Rigatos, S.K.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival</title><author>Samantas, E. ; Dervenis, C. ; Rigatos, S.K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-bd6d3e0e0461b6f65cb66a0a838aa20a062f2d647cdb4449894ef8275bc801ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Chemotherapy, Adjuvant</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Drug Administration Routes</topic><topic>Humans</topic><topic>Neoplasm Staging</topic><topic>Review Article</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samantas, E.</creatorcontrib><creatorcontrib>Dervenis, C.</creatorcontrib><creatorcontrib>Rigatos, S.K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samantas, E.</au><au>Dervenis, C.</au><au>Rigatos, S.K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival</atitle><jtitle>Digestive diseases (Basel)</jtitle><addtitle>Dig Dis</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>25</volume><issue>1</issue><spage>67</spage><epage>75</epage><pages>67-75</pages><issn>0257-2753</issn><eissn>1421-9875</eissn><isbn>3805582722</isbn><isbn>9783805582728</isbn><eisbn>3318014575</eisbn><eisbn>9783318014570</eisbn><abstract>Clear progress has been made in the adjuvant treatment of colon cancer. Until very recently, the absolute benefit for survival obtained with the administration of 6 months’ FU/LV compared with control was about 6%. Fluoropyrimidines have been shown to be at least as active and can replace intravenous FU/LV in stage III colon cancer. Based on the results of the MOSAIC and NSABP C-07 trials, the addition of oxaliplatin to FU/LV improves disease-free survival and FOLFOX for 6 months can be recommended as adjuvant treatment for patients with stage III colon cancer. The benefit of adjuvant chemotherapy in stage II disease is limited and it should be proposed in patients with high-risk features. Adjuvant treatment of colon cancer improving and the use of genetic/molecular markers with the new targeted therapies may further improve survival.</abstract><cop>Basel, Switzerland</cop><pmid>17384510</pmid><doi>10.1159/000099172</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0257-2753 |
| ispartof | Digestive diseases (Basel), 2007-01, Vol.25 (1), p.67-75 |
| issn | 0257-2753 1421-9875 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000099172 |
| source | Karger Journals; MEDLINE; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - therapeutic use Chemotherapy, Adjuvant Colonic Neoplasms - drug therapy Drug Administration Routes Humans Neoplasm Staging Review Article Survival Analysis |
| title | Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T22%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20Chemotherapy%20for%20Colon%20Cancer:%20Evidence%20on%20Improvement%20in%20Survival&rft.jtitle=Digestive%20diseases%20(Basel)&rft.au=Samantas,%20E.&rft.date=2007-01-01&rft.volume=25&rft.issue=1&rft.spage=67&rft.epage=75&rft.pages=67-75&rft.issn=0257-2753&rft.eissn=1421-9875&rft.isbn=3805582722&rft.isbn_list=9783805582728&rft_id=info:doi/10.1159/000099172&rft_dat=%3Cproquest_cross%3E70303437%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&rft.eisbn=3318014575&rft.eisbn_list=9783318014570&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70303437&rft_id=info:pmid/17384510&rfr_iscdi=true |